At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 176 enrolled
Drug / intervention
Candesartan +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
CAndesartan vs LIsinopril Effects on the BRain and Endothelial Function in eXecutive MCI (CALIBREX)
In Brief
A Phase 2 clinical trial evaluating Candesartan and Lisinopril for Hypertension and Mild Cognitive Impairment. Completed, enrolled 176 participants across 1 site.
Detailed Summary
The aim of this study is to conduct a 1-year double blind randomized control trial comparing candesartan to lisinopril in 140 individuals with hypertension and executive mild cognitive impairment in their effects on executive function, neuroimaging markers, and vascular indicators.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension, Mild Cognitive Impairment
CountriesUnited States
CollaboratorsNational Institute on Aging (NIA)
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedNov 2013
Enrollment StartAug 2014
Primary CompletionDec 2018
TodayJul 2026
First PostedNov 14, 2013
Enrollment StartAug 20, 2014
Primary CompletionDec 3, 2018
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 12.6 years ago
Interventions
Candesartandrug
blinded
Lisinoprildrug
Blinded